<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393756</url>
  </required_header>
  <id_info>
    <org_study_id>(R2-CHOP2)</org_study_id>
    <nct_id>NCT01393756</nct_id>
  </id_info>
  <brief_title>Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma</brief_title>
  <acronym>R2-CHOP2</acronym>
  <official_title>A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of the association of Lenalidomide&#xD;
      (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone)&#xD;
      in a population of patients with follicular lymphoma as measured by the response rate at the&#xD;
      end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CR+CRu)</measure>
    <time_frame>at the end of complete treatment, average of 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from the date of inclusion, average of 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from the date of first documentation of a response, average of 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide dose 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and R-CHOP</intervention_name>
    <description>Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.</description>
    <arm_group_label>Lenalidomide dose 25 mg</arm_group_label>
    <other_name>R2-CHOP2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with follicular lymphoma, (WHO) grade 1, 2 or 3a with at least one of the&#xD;
             following signs requiring initiation of treatment:&#xD;
&#xD;
               -  Bulky disease according to the GELF criteria: nodal or extra-nodal mass &gt;7cm in&#xD;
                  its greater diameter&#xD;
&#xD;
               -  B symptoms&#xD;
&#xD;
               -  Elevated serum (LDH) or beta 2-microglobulin&#xD;
&#xD;
               -  Involvement of at least 3 nodal sites (each &gt;3cm)&#xD;
&#xD;
               -  Symptomatic spleen enlargement&#xD;
&#xD;
               -  Compressive syndrome&#xD;
&#xD;
               -  Pleural or peritoneal effusion&#xD;
&#xD;
          -  Aged from 18 to 70 years&#xD;
&#xD;
          -  WHO performance status 0, 1 or 2&#xD;
&#xD;
          -  Signed inform consent&#xD;
&#xD;
          -  Life expectancy of ≥ 90 days (3 months).&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)† must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 25 mIU/mL not more than 3 days from the&#xD;
             start of study drug and must either commit to continued abstinence from heterosexual&#xD;
             intercourse (and confirmed on a monthly basis) or begin one effective method of birth&#xD;
             control, at least four weeks before she starts taking lenalidomide, and maintain that&#xD;
             method throughout the entire duration of study drug therapy (including dose&#xD;
             interruptions), and for four weeks after the end of study treatment with lenalidomide,&#xD;
             even if she has amenorrhea. FCBP must also agree to pregnancy testing at least every&#xD;
             three weeks and must be counseled at a minimum of every three weeks about pregnancy&#xD;
             precautions and risks of fetal exposure.&#xD;
&#xD;
          -  Men must agree not to father a child and agree to use a condom throughout study drug&#xD;
             therapy, during any dose interruption, and for one week after cessation of study drug&#xD;
             therapy, if their partner is pregnant or of child bearing potential. Men must also&#xD;
             agree not to donate semen during study drug therapy and for one week after end of&#xD;
             study drug therapy. Men must be counseled at a minimum of every 4 weeks about&#xD;
             pregnancy precautions and risks of fetal exposure.&#xD;
&#xD;
          -  All subjects must abstain from donating blood while taking study drug therapy and for&#xD;
             one week following discontinuation of study drug therapy.&#xD;
&#xD;
          -  Agree not to share study drug with another person and to return all unused study drug&#xD;
             to the investigator.&#xD;
&#xD;
               -  A female patient is considered to have childbearing potential unless she meets at&#xD;
                  least one of the following criteria 1) Age ≥ 50 years and naturally amenorrhoeic&#xD;
                  for ≥ 1 year (amenorrhoea following cancer therapy does not rule out childbearing&#xD;
                  potential); or 2) Premature ovarian failure confirmed by a specialist&#xD;
                  gynaecologist or 3) Previous bilateral salpingo-oophorectomy (BSO), or&#xD;
                  hysterectomy, or 4) XY genotype, turner syndrome, uterine agenesis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with immunotherapy or chemotherapy:&#xD;
&#xD;
               -  Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if&#xD;
                  stopped more than one year before inclusion&#xD;
&#xD;
               -  Rituximab alone during less than three months, if stopped more than one year&#xD;
                  before inclusion&#xD;
&#xD;
          -  Previous radiotherapy except if localized to one lymph node area&#xD;
&#xD;
          -  Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative&#xD;
&#xD;
          -  Central nervous system or meningeal involvement&#xD;
&#xD;
          -  Contraindication to any drug contained in the chemotherapy regimen&#xD;
&#xD;
          -  (HIV) disease, active hepatitis B or C&#xD;
&#xD;
          -  Any serious active disease or co-morbid medical condition (according to investigator's&#xD;
             decision)&#xD;
&#xD;
          -  Any of the following laboratory abnormalities.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,500 cells/mm3 (1.5 x 109/L).&#xD;
&#xD;
               -  Platelet count &lt; 100,000/mm3 (100 x 109/L).&#xD;
&#xD;
               -  Serum (SGOT/AST) or (SGPT/ALT) 5.0 x upper limit of normal (ULN).&#xD;
&#xD;
               -  Serum total bilirubin &gt; 2.0 mg/dL (34 µmol/L), except in case of hemolytic&#xD;
                  anemia.&#xD;
&#xD;
          -  Calculated creatinine clearance (Cockcroft-Gault formula) of &lt; 50 mL /min&#xD;
&#xD;
          -  Prior history of malignancies other than lymphoma (except for basal cell or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the&#xD;
             subject has been free of the disease for ≥ 3 years&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide.&#xD;
&#xD;
          -  Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.&#xD;
&#xD;
          -  Subjects with ≥ Grade 2 neuropathy.&#xD;
&#xD;
          -  Prior use of lenalidomide.&#xD;
&#xD;
          -  Use of any standard or experimental anti-cancer drug therapy within 28 days of the&#xD;
             initiation (Day 1) of study drug therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé TILLY, Professeur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri BECQUEREL</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Brabois</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.lysa-lymphoma.org/</url>
    <description>Lymphoma Study Association LYSA</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

